Rosa María Alcobendas Rueda

WA42985: A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of Obinutuzumab in combination with mycophenolate mofetil and corticosteroids in adolescents with active class III or IV lupus nephritis.

I4V-MC-JAHW: Phase III. Open-label, active-controlled study of the safety and efficacy of oral baricitinib in patients aged 2 years to less than 18 years with active uveitis associated with juvenile idiopathic arthritis or antinuclear antibody-positive chronic anterior uveitis.

A3921165: Efficacy, safety, tolerability and pharmacokinetics of tofacitinib for the treatment of systemic juvenile idiopathic arthritis (sJIA) with active systemic features in children and adolescents.

AMGEN - 20190530: Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study followed by an active treatment phase to evaluate the efficacy and safety of Apremilast in children 2 to less than 18 years of age with active Behçet's disease-associated oral ulcers (BEAN).

SOBI NI-0501-14 (ESMERALDA): Open-label, multicenter, two-cohort, single-arm study to evaluate the efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult Still's disease) or with MAS in systemic lupus erythematosus.